Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Latrepirdine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 16/20 | 0.98 |
| ▸ | HTR6 known ✓ | P50406 | 16/20 | 0.98 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.98 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.98 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.98 |
| ▸ | HTR7 known ✓ | P34969 | 3/20 | 0.98 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.98 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.98 |
| ▸ | BCHE known ✓ | P06276 | 1/20 | 0.98 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.98 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.98 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.98 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.98 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.98 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.98 |
| ▸ | HTR1E known ✓ | P28566 | 1/20 | 0.98 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.98 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.98 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.98 |
| ▸ | HTR5A known ✓ | P47898 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Latrepirdine SCHEMBL3733639 | 1.00 | HRH1 (0.98) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| Latrepirdine SCHEMBL29717582 | 1.00 | HRH1 (0.98) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| Latrepirdine SCHEMBL30783244 | 1.00 | HRH1 (0.98) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| Latrepirdine SCHEMBL292354 | 0.99 | HRH1 (1.00) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| Latrepirdine SCHEMBL29717663 | 0.99 | HRH1 (1.00) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| Latrepirdine SCHEMBL29717625 | 0.99 | HRH1 (1.00) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| Latrepirdine SCHEMBL29357222 | 0.99 | HRH1 (1.00) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| Dorastine SCHEMBL3264836 | 0.93 | HRH1 (0.89) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| Latrepirdine SCHEMBL13320188 | 0.93 | HRH1 (0.89) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| Latrepirdine SCHEMBL13320249 | 0.93 | HTR6 (0.89) | HRH1HTR6ADRA2AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101121-A1 | DRUG DEMONSTRATING ANXIOLYTIC EFFECT BASED ON HYDROGENATED PYRIDO (4,3-B) INDOLES, ITS PHARMACOLOGICAL COMPOUND AND APPLICATION METHOD | Medivation Neurology ,Inc. | 2012-04-26 | — | — | US | claimed |
| EP-2086538-B1 | COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE USING DIMEBON AND DONEPEZIL | MEDIVATION NEUROLOGY INC (US) | 2012-03-14 | — | — | EP | claimed |
| EP-2420235-A1 | Methods and combination therapies for treating alzheimer's disease | Medivation Neurology, Inc. (US) | 2012-02-22 | — | — | EP | claimed |
| US-20110112132-A1 | MEANS FOR THE TREATMENT OF ACUTE AND CHRONIC DISORDERS OF CEREBRAL CIRCULATION, INCLUDING INSULT, BASED ON HYDROGENATED PYRIDO (4,3-B) INDOLES (VARIANTS), PHARMACOLOGICAL MEANS BASED THEREON AND METHOD FOR THE USE THEREOF | MEDIVATION NEUROLOGY, INC. | 2011-05-12 | — | — | US | claimed |
| US-20100286188-A1 | MEANS FOR IMPROVING COGNITIVE FUNCTIONS AND MEMORY BASED ON HYDROGENATED PYRIDO(4,3-B)INDOLES (VARIANTS), PHARMACOLOGICAL MEANS BASED THEREON AND METHOD FOR THE USE THEREOF | BACHURIN SERGEY O | 2010-11-11 | — | — | US | claimed |
| US-20100152108-A1 | METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE | MEDIVATION NEUROLOGY, INC. (US) | 2010-06-17 | — | — | US | claimed |
| US-20100152225-A1 | HYDROGENATED PYRIDO [4,3-B] INDOLES SUCH AS DIMEBON FOR TREATING CANINE COGNITIVE DYSFUNCTION SYNDROME | MEDIVATION NEUROLOGY, INC. | 2010-06-17 | — | — | US | claimed |
| US-20100099700-A1 | HYDROGENATED PYRIDO (4,3-B) INDOLES FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) | MEDIVATION NEUROLOGY, INC. | 2010-04-22 | — | — | US | claimed |
| EP-2086538-A2 | COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE USING I.A. DIMEBON AND DOLEPEZIL | Medivation Neurology, Inc. (US) | 2009-08-12 | — | — | EP | claimed |
| EP-2066322-A2 | HYDROGENATED PYRIDO [4,3-B] INDOLES SUCH AS DIMEBON FOR TREATING CANINE COGNITIVE DYSFUNCTION SYNDROME | Medivation Neurology, Inc. (US) | 2009-06-10 | — | — | EP | claimed |
| WO-2008051599-A2 | COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE USING I. A. DIMEBON AND DOLEPEZIL | MEDIVATION NEUROLOGY, INC. (US) | 2008-05-02 | — | — | WO | claimed |
| WO-2008036400-A2 | HYDROGENATED PYRIDO [4,3-B] INDOLES SUCH AS DIMEBON FOR TREATING CANINE COGNITIVE DYSFUNCTION SYNDROME | MEDIVATION NEUROLOGY, INC. (US) | 2008-03-27 | — | — | WO | claimed |
| WO-2008036410-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) | MEDIVATION NEUROLOGY, INC. (US) | 2008-03-27 | — | — | WO | claimed |
| US-20070225316-A1 | Methods and compositions for treating schizophrenia | MEDIVATION, INC. | 2007-09-27 | — | — | US | claimed |
| US-20070179174-A1 | Methods and compositions for slowing aging | MEDIVATION, INC. | 2007-08-02 | — | — | US | claimed |
| US-20070117835-A1 | Methods and compositions for treating Huntington's disease | MEDIVATION NEUROLOGY, INC. | 2007-05-24 | — | — | US | claimed |
| US-20070117834-A1 | Methods and compositions for treating Huntington's disease | MEDIVATION NEUROLOGY, INC. | 2007-05-24 | — | — | US | claimed |
| WO-2007041697-A2 | HYDROGENATED PYRIDO-INDOLE COMPOUNDS FOR THE TREATMENT OF HUNTINGTON ' S DISEASE | MEDIVATION, INC. (GB) | 2007-04-12 | — | — | WO | claimed |
| EP-1692131-A2 | METHODS AND COMPOSITIONS FOR SLOWING AGING | MEDIVATION, INC. (US) | 2006-08-23 | — | — | EP | claimed |
| WO-2005055951-A2 | METHODS AND COMPOSITIONS FOR SLOWING AGING | MEDIVATION, INC. (US) | 2005-06-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152108-A1 | METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE | PSEN2, APP, PSEN1 | HRH1 667/4885HTR6 6/4885ADRA2A 553/4885 |
| US-20070225316-A1 | Methods and compositions for treating schizophrenia | SLC6A3, DBH, GRIN3B | HRH1 2918/4885HTR6 4/4885ADRA2A 976/4885 |
| US-20070179174-A1 | Methods and compositions for slowing aging | PRDX5, HMOX1, SHMT2 | HRH1 2638/4885HTR6 80/4885ADRA2A 1913/4885 |
| US-20070117835-A1 | Methods and compositions for treating Huntington's disease | HTT, HYPK, HTR6 | HRH1 388/4885HTR6 3/4885ADRA2A 3695/4885 |
| US-20100152225-A1 | HYDROGENATED PYRIDO [4,3-B] INDOLES SUCH AS DIMEBON FOR TREATING CANINE COGNITIVE DYSFUNCTION SYNDROME | HPD, KYNU, IDO1 | HRH1 179/4885HTR6 5/4885ADRA2A 2203/4885 |
| US-20110112132-A1 | MEANS FOR THE TREATMENT OF ACUTE AND CHRONIC DISORDERS OF CEREBRAL CIRCULATION, INCLUDING INSULT, BASED ON HYDROGENATED PYRIDO (4,3-B) INDOLES (VARIANTS), PHARMACOLOGICAL MEANS BASED THEREON AND METHOD FOR THE USE THEREOF | TPH1, TPH2, HTR6 | HRH1 754/4885HTR6 3/4885ADRA2A 377/4885 |
| US-20100099700-A1 | HYDROGENATED PYRIDO (4,3-B) INDOLES FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) | HTT, NLN, SMN1; SMN2 | HRH1 252/4885HTR6 29/4885ADRA2A 3518/4885 |
| US-20070117834-A1 | Methods and compositions for treating Huntington's disease | HTT, HYPK, HTR6 | HRH1 388/4885HTR6 3/4885ADRA2A 3695/4885 |
| US-20120101121-A1 | DRUG DEMONSTRATING ANXIOLYTIC EFFECT BASED ON HYDROGENATED PYRIDO (4,3-B) INDOLES, ITS PHARMACOLOGICAL COMPOUND AND APPLICATION METHOD | TPH1, TPH2, HTR3B | HRH1 708/4885HTR6 11/4885ADRA2A 151/4885 |
| US-20100286188-A1 | MEANS FOR IMPROVING COGNITIVE FUNCTIONS AND MEMORY BASED ON HYDROGENATED PYRIDO(4,3-B)INDOLES (VARIANTS), PHARMACOLOGICAL MEANS BASED THEREON AND METHOD FOR THE USE THEREOF | HTR6, TPH1, IDO1 | HRH1 557/4885HTR6 1/4885ADRA2A 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.